Christine Brennan

Christine Brennan has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Managing Director at Vertex Ventures HC (VVHC), based in Boston, leading global healthcare investments in biotech and medtech.

She was a board observer for Adagio [NASDAQ:ADGI], LifeMine Therapeutics, PAQ Therapeutics and Translate Bio [NASDAQ:TBIO].

Prior to MRL Ventures Fund, she was Principal at the Novartis Venture Fund from 2013-2017 where she served on the board of directors for Altimmune [NASDAQ:ALT] and a board observer for several companies including ROX Medical, lnnocrin Pharmaceuticals, Viamet Pharmaceuticals and Quartet Medicine.

Prior to Novartis Venture Fund, she was Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also held positions in business development and marketing at small and mid-size biopharmaceutical companies.

Christine received her PhD in neuroscience from Dartmouth Medical School and was a post-doctoral fellow in developmental neurobiology at the National Institutes of Health.